Dublin, May 07, 2026 (GLOBE NEWSWIRE) — The “Asparlas (calaspargase pegol) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts” has been added to ResearchAndMarkets.com’s offering.
The Asparlas (calaspargase pegol) market is experiencing robust growth, projected to expand from $1.26 million in 2025 to $1.37 million in 2026 at a compound annual growth rate (CAGR) of 8.9%. By 2030, it’s expected to reach $1.91 million with a CAGR of 8.6%. This growth is largely driven by the increasing success of asparaginase in treating acute lymphoblastic leukemia (ALL), advancements in enzyme stabilization technologies, and the expansion of pediatric oncology programs.
The current trends include a growing focus on pegylated asparaginase therapies, particularly for pediatric ALL treatment protocols. This, coupled with advancements in enzyme-based oncology drugs, positions Asparlas as a vital player in the market. Rising incidence rates of ALL, due to enhanced diagnostic techniques, awareness, and genetic predispositions, are contributing to this market expansion. In 2024, the American Cancer Society projected approximately 62,770 new leukemia cases in the U.S., indicating increased demand for effective treatments like Asparlas.
Healthcare expenditure is another key factor propelling market growth. Increased funding broadens access to advanced leukemia treatments, as demonstrated by a 5.6% rise in healthcare spending reported by the UK’s Office for National Statistics for 2023. Moreover, the surge in personalized medicine, driven by a deeper understanding of genetic variations, is boosting the adoption of Asparlas, which offers tailored treatment regimes for better patient outcomes. The Personalized Medicine Coalition highlighted a significant rise in FDA-approved treatments from six in 2022 to 16 in 2023, indicating a strong trend toward personalized healthcare solutions.
Servier Pharmaceuticals LLC is a major player in this market. North America led in market size in 2025, while Asia-Pacific is anticipated to be the fastest-growing region. The regions analyzed include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, covering countries like Australia, India, China, South Korea, Japan, the UK, France, Germany, the USA, and Canada.
Tariffs have impacted the Asparlas market by increasing the cost of imported biologic materials, evident in Asia Pacific and Latin America. However, these tariffs have prompted regional manufacturing of oncology drugs, enhancing supply chain localization. The Asparlas market report provides comprehensive statistics, including market size, regional shares, and industry trends, delivering critical insights for stakeholders aiming to thrive in this sector.
Asparlas is primarily used to treat certain types of ALL, targeting leukemia cells by depleting asparagine. Available in powder and injectable forms, Asparlas is distributed through numerous channels, including hospital and retail pharmacies, catering to both adult and pediatric patients. The market values reflect ‘factory gate’ values, encompassing goods and related services sold across various sectors.
The Asparlas market continues to develop, supported by increasing global demand for improved treatment options, making it a significant field of interest for ongoing medical and commercial investment.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $1.37 Million |
| Forecasted Market Value (USD) by 2030 | $1.91 Million |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/5v7n0h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Asparlas (calaspargase pegol) Market
